professor of rheumatology UCL
London, England
Joined June 2013
- Tweets129
- Following233
- Followers408
- Likes465
Here are some of the team talking about our new clinical trial STRATIFY lupus @SLEuroSociety Lisbon @MuhammadShipa
Michael Ehrenstein retweeted
Here are some of the team talking about our new clinical trial STRATIFY lupus @SLEuroSociety Lisbon @MuhammadShipa
Just out! We challenge the prevailing caution and advocate for a biomarker-guided approach soon to be tested in the STRATIFY lupus trial: Rituximab–belimumab combination for refractory SLE #lupus #PrecisionMedicine @MuhammadShipa @VersusArthritis
thelancet.com/journals/lanrh…
Michael Ehrenstein retweeted
Are you a rheumatologist or nephrologist looking after patients with #lupus #nephritis in the UK?
We would like to invite you to take part in our research study to understand how treatment decisions are made.
bit.ly/LNstudyUk
@lupusUK @UKKidney
Validation and mechanistic insights for IgA2 as a companion biomarker of combination belimumab after rituximab for #lupus supporting the upcoming STRATIFY lupus trial cell.com/cell-reports-medici…
Michael Ehrenstein retweeted
A very productive 2-Day #BILAG #lupus meeting in Leeds to enhance recruitment of @NIHRresearch FIRST and @VersusArthritis @NIHRresearch @The_MRC STRATIFY-LUPUS - two trials opening in UK in 2026. Discussed Treat-to-Target & inspiring the next generation Lupus Leaders @LUPUSUK 🦋
STRATIFY lupus: personalised care for patients | NIHR- a big thank you to all the lupus specialists and their patients who made this research possible as well as @VersusArthritis and @GSK nihr.ac.uk/story/stratify-lu…
Michael Ehrenstein retweeted
📷🎉Exciting news!
Mike and I have been awarded a new grant to lead the STRATIFY Lupus—the FIRST EVER biomarker-enriched trial in lupus!
We’ll use biomarkers (IgA2 anti-DNA) to predict who responds best to treatment. @VersusArthritis, @NIHRresearch EME, @GSK , and @LUPUSUK
Michael Ehrenstein retweeted
NEW REVIEW—@LucyCarter6, @MikeEhrenstein & @edvital discuss the evolution and trajectory of B-cell targeted therapies in rheumatic diseases bit.ly/4hfPCP8
Research Fellow in immunology/rheumatology at UCL jobs.ac.uk/job/DLN096/resear…
Exciting #researchopportunity to join our group to work on the #Immunology of #lupus working on biomarkers and mechanisms of response to B cell targeted therapies with @MuhammadShipa @louisakjames ucl.ac.uk/work-at-ucl/search…
Thanks to @VersusArthritis and NIHR who have just agreed to jointly provide £1.7M to support a precision medicine trial in #lupus. Thanks to @GSK for providing free belimumab, and to all the UK lupus experts for agreeing to help recruit patients. #WorldLupusDay @NIHR_Industry
And a big shout out to @MuhammadShipa who has helped to make the STRATIFY lupus trial possible and will be joining @DoM_UCL as a Principal Research Fellow and consultant rheumatologist.
Important research from @Dr_JohnR and colleagues highlighting the differences in management approaches for #lupus nephritis within the UK and that rituximab remains the most popular choice for refractory renal disease academic.oup.com/rheumap/art…
Michael Ehrenstein retweeted
Academic clinician–scientists risk becoming an endangered species.
World View from @StephenORahilly @Cambridge_Uni
nature.com/articles/s41591-0…
Very proud of @MuhammadShipa who successfully defended his thesis this afternoon. Well done! Thanks to @VersusArthritis and @LUPUSUK for supporting his research.
Michael Ehrenstein retweeted
Clinical trials provide a unique substrate to understand pathogenesis and identify biomarkers to targeted therapies in #SLE which can be used to stratify patients. Taken from a new Viewpoint by @MikeEhrenstein and @MuhammadShipa: rupress.org/jem/article/220/…
Well done @MuhammadShipa for the nomination from Department of Inflammation for the @DoM_UCL research award. Good luck! ucl.ac.uk/medicine/news-and-…